Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine.
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 7, 2025 NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.34 | 2.61131570137 | 89.61 | 93.77 | 88 | 986823 | 90.89052676 | CS |
4 | 9.46 | 11.4680567341 | 82.49 | 93.77 | 77.52 | 1271893 | 86.74812978 | CS |
12 | -11.26 | -10.9097955624 | 103.21 | 107.305 | 77.52 | 1345293 | 88.91795072 | CS |
26 | 11.72 | 14.6080019943 | 80.23 | 121.055 | 70.45 | 1122355 | 96.80457169 | CS |
52 | 21.35 | 30.2407932011 | 70.6 | 121.055 | 58.1 | 951302 | 86.91151454 | CS |
156 | 74.13 | 415.993265993 | 17.82 | 121.055 | 17.44 | 759782 | 60.55019358 | CS |
260 | 68.39 | 290.280135823 | 23.56 | 121.055 | 15.51 | 579626 | 55.54701247 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales